A artrite reumatóide é uma doença inflamatória crônica associada a alta morbidade, perda da produtividade e redução da expectativa de vida. Os pacientes requerem uma atendimento multidisciplinar para o controle da doença, reduzindo a inflamação e prevenindo a atrofia e deformação articulares. A estimulação elétrica nervosa transcutânea (TENS) tem se demonstrado no controle da dor articular, mas ainda há controvérsias sobre sua eficácia na reabilitação funcional da mão nesses pacientes. Este é um estudo cego, placebo-controlado, cruzado para comparar parâmetros funcionas da mobilidade da mão em pacientes com artrite reumatóide antes, durante e ao final de um período de 12 semanas de aplicação de TENS-burst em pontos sensitivos do membro superior. Na aplicação terapêutica utilizou-se intensidade de corrente de 10mA para estimulação das articulações metacarpofalangeanas e 20mA para os pontos sensorias do braço. Após uma pausa de um mês no tratamento, os pacientes que inicialmente receberam a estimulação terapêutica passaram a receber a estimulação placebo e vice-versa. Os resultados mostraram que a eletroestimulação terapêutica produziu mudanças positivas graduais e lineares na reabilitação funcional da mão analisado-se parâmetros de força e precisão de preensão das mãos, levando os pacientes à uma independência na execução de atividade de vida diária. O tratamento placebo mostrou-se ineficiente para a recuperação dos parâmetros avaliados. As habilidades conquistadas pelos pacientes que receberam inicialmente a eletroestimulação terapêutica foram perdidas durante o período de repouso, sugerindo que a manutenção da função da mão depende da continuidade do tratamento ao longo do tempo / Rheumatoid arthritis is a chronic inflammatory disease associated with high morbidity, loss of productivity and reduced life expectancy. Patients require multidisciplinary treatment to control the disease by reducing inflammation and preventing atrophy and joint deformation. Transcutaneous electrical nerve stimulation (TENS-burst) has been shown to control joint pain, but there is still controversy about its efficacy in functional hand rehabilitation in these patients. This is a blind, placebo-controlled, crossover study to compare the functional parameters of the mobility of the hand in rheumatoid arthritis patients before, during and after a period of 12 weeks of application of TENS- burst in the sensory points of the arm and metacarpophalangeal joints . In therapeutic application we used a current of 10mA for stimulation of joints and 20mA for the sensory points of the arm. After a month-long pause in treatment, patients who initially received therapy stimulation began receiving the placebo stimulation and vice versa. The results showed that therapeutic electrical stimulation produced gradual and linear positive changes in functional rehabilitation of the hand, accessed by analysis of strength and accuracy parameters of prehension, leading patients to independence in performing their daily living activities. The placebo treatment was inefficient for the recovery of the parameters evaluated. Skills achieved by patients who initially received therapeutic TENS-burst were lost during the rest (washing out) period, suggesting that the maintenance of hand function in rheumatoid artherits patients depends on the continuity of TENS-burst treatment

Recomendações para rastreamento de Tuberculoses Latente (TBL) em pacientes que receberão tratamento com antagonistas do TNF-alfa (anti- TNF) permanecem controversas para regiões endêmicas Objetivo: Esse estudo buscou demonstrar a eficácia em longo prazo do rastreamento e tratamento da TBL em pacientes portadores de Artrite Reumatoide (AR) recebendo anti-TNF. Métodos: 202 pacientes com AR, antes do início do anti-TNF, foram rastreados para TBL por meio do teste tuberculínico (TT), Radiografia de tórax (RX) e história de prévia de exposição à tuberculose (EXP). Todos os pacientes foram seguidos com intervalos de um a três meses. Resultados: 85 pacientes (42%) foram tratados com um único agente anti-TNF e 117 pacientes (58%) mudaram de anti-TNF uma ou duas vezes. O rastreamento para TBL foi positivo em 66 pacientes, 44 apresentaram TT positivo, 23 apresentavam história de exposição (EXP), e 14, alterações radiográficas (RX). EXP isoladamente foi responsável por 14 diagnósticos em pacientes TT negativos. Pacientes portadores de TBL receberam tratamento com Isoniazida (300 mg/dia por seis meses) e nenhum deles desenvolveu TB. Durante os seguimentos, o TT foi repetido em 51 pacientes. A conversão foi observada em cinco: três foram diagnosticados com TBL e dois com TB ativa (14 e 36 meses após receber terapia anti-TNF), sugerindo nova exposição a TB. Conclusão: O rastreamento e tratamento da TBL antes do início da terapia com anti-TNF é efetiva em regiões endêmicas, e reforça a relevância da história de contato com TB para o diagnóstico da TBL em pacientes com AR / Recommendations for screening of latent tuberculosis infection (LTBI) in patients eligible for anti-TNF agents remain unclear in endemic regions. Objective: This study aimed to evaluate the long-term efficacy of LTBI screening/treatment in patients with rheumatoid arthritis (RA) receiving TNF blockers. Design: 202 RA patients were screened for LTBI prior to receiving anti-TNF treatment, by means of tuberculin skin test (TST), chest radiography (X-Ray), and history of tuberculosis exposure (EXP). All subjects were regularly followed at 1- to 3-month intervals. Results: Eighty-five patients (42%) were treated with a single anti-TNF agent, and 117 patients (58%) switched anti-TNF agents once or twice. LTBI screening was positive in 66 patients, 44 presented positive TST, 23 had a history of EXP, and 14, abnormal X-Ray. Exposure alone accounted for LTBI diagnosis in 14 patients with negative TSTs. LTBI patients were treated with Isoniazid (300 mg/day during six months) and none developed TB. During follow up, TST was repeated in 51 patients. Conversion was observed in five: three were diagnosed with LTBI and two with active TB (14 and 36 months after receiving anti-TNF therapy, suggesting new TB exposure). Conclusion: LTBI screening and treatment prior to anti-TNF treatment is effective in endemic areas and reinforces the relevance of contact history for diagnosing LTBI in RA patients

Introdução: A vacinação contra a influenza pandêmica A/H1N1 resultou em soroproteção em mais de 85% dos indivíduos saudáveis. Entretanto, dados em pacientes com artrite reumatoide (AR) são escassos. Objetivos: O objetivo deste estudo é avaliar a imunogenicidade e a segurança em curto prazo da vacina contra influenza pandêmica A/H1N1 em pacientes com AR e a influência da atividade da doença e da medicação nesta resposta. Métodos: Trezentos e quarenta pacientes adultos com AR em seguimento e tratamento regular e 234 controles saudáveis foram examinados antes e 21 dias após receber uma dose da vacina sem adjuvante contra influenza A/California/7/2009. A atividade da doença (DAS28), o tratamento em uso e os títulos de anticorpos também foram avaliados. As taxas de soroproteção (títulos de anticorpos >= 1:40) e soroconversão (percentagem de pacientes com aumento de título de anticorpos maior ou igual a 4, se o título pré- vacinal fosse maior ou igual a 1:10; ou título pós-vacinal de pelo menos 1:40, se o título pré-vacinal era menor que 1:10), as médias geométricas dos títulos (MGT) e o fator de incremento das médias geométricas (FI-MGT) foram calculados. Os eventos adversos foram também registrados. Resultados: Os pacientes com AR e os controles tinham taxas pré-vacinais de soroproteção (10,8% vs. 11,5%) e MGT (8,0 vs. 9,3) comparáveis (p>0,05). Após a vacinação, foi observada redução significativa na resposta dos pacientes com AR versus controles (p<0,001) em todos os desfechos sorológicos: taxas de soroproteção (60,0 vs. 82,9%) e soroconversão (53,2% vs. 76,9%), MGT (57,5 vs. 122,9) e FI-MGT (7,2 vs. 13,2). A atividade de doença não prejudicou a soroproteção ou a soroconversão e se manteve estável em 97,4% dos pacientes. O metotrexato e o abatacepte foram associados à redução da resposta vacinal. A vacinação foi bem tolerada, com poucos efeitos adversos. Conclusão: Os dados confirmaram tanto a segurança em curto prazo como, diferente da maioria dos trabalhos com influenza sazonal, a redução da soroproteção em pacientes com AR, não relacionada à atividade de doença e à maioria das medicações em uso (com exceção do metotrexato e do abatacepte). A extrapolação da resposta imunológica de uma vacina para outra pode não ser possível e estratégias específicas de imunização (possivelmente em duas doses) podem ser necessárias / Background: Pandemic influenza A/H1N1 vaccination yielded seroprotection in more than 85% of healthy individuals. However, similar data are scarce in rheumatoid arthritis (RA) patients. Objectives: The objective of this study is to evaluate the immunogenicity and the short-term safety of anti- pandemic influenza A/H1N1 vaccine in RA patients, and the influence of disease activity and medication to the response. Methods: Three hundred and forty adult RA patients in regular follow-up and treatment, and 234 healthy controls were assessed before and 21 days after adjuvant-free influenza A/California/7/2009 vaccine. Disease activity (DAS28), current treatment and anti-pandemic influenza A/H1N1 antibody titres were also evaluated. Seroprotection (antibody titre >=1:40) and seroconversion (the percentage of patients with a fourfold or greater increase in antibody titre, if prevaccination titre was 1:10 or greater, or a postvaccination titre of 1:40 or greater, if prevaccination titre was less than 1:10) rates, geometric mean titres (GMT) and factor increase in geometric mean titre (FI-GMT) were calculated and adverse events registered. Results: RA patients and controls showed similar (p>0.05) prevaccination seroprotection (10.8% vs. 11.5%) and GMT (8.0 vs. 9.3). After vaccination a significant reduction (p<0.001) was observed in all endpoints in RA patients versus controls: seroprotection (60.0 vs. 82.9%; p<0.0001) and seroconversion (53.2% vs. 76.9%) rates, GMT (57.5 vs. 122.9) and FI-GMT (7.2 vs. 13.2). Disease activity did not preclude seroprotection or seroconversion and remained unchanged in 97.4% of patients. Methotrexate and abatacept were associated with reduced responses. Vaccination was well tolerated with minimal adverse events. Conclusions: The data confirmed both short-term anti-pandemic A/H1N1 vaccine safety and, different from most studies with seasonal influenza, reduced seroprotection in RA patients, unrelated to disease activity and to most medications (except methotrexate and abatacept). Extrapolation of xii immune responses from one vaccine to another may therefore not be possible and specific immunization strategies (possibly booster) may be needed

Besides the molecular mechanisms regulating activation of FLS mentioned above, we also investigated anti-inflammatory activities of Chinese herbal medicine sinomenine and Liang Miao San on activated human FLS in RA. Sinomenine, an alkaloid isolated from the root of Sinomenium acutum, has been used to alleviate the symptoms of rheumatic diseases. Liang Miao San (LMS), composed of the herbs Rhizoma Atractylodis (Cangzhu) and Cotex Phellodendri (Huangbai), is another traditional Chinese medicine formula for RA treatment. Since the potential anti-inflammatory activities of sinomenine and LMS have been demonstrated, we investigated the in vitro anti-inflammatory effects of sinomenine and LMS on inflammatory cytokine TNF-alpha activation of human normal and RA-FLS and the underlying intracellular mechanisms. In the present study, sinomenine was found to significantly inhibit TNF-alpha induced cell surface expression of VCAM-1 and release of inflammatory cytokine and chemokine IL-6, CCL2 and CXCL8 from both normal and RA-FLS (all p &lt; 0.05). Our results provide a new insight into the differential anti-inflammatory activities of sinomenine and LMS through the suppression of TNF-alpha activated FLS by modulating distinct intracellular signaling pathways in RA, and help to provide a biochemical basis for the development of a cost-effective human synoviocyte model for the future screening of traditional Chinese medicine (TCM) possessing potential anti-rheumatic activities. (Abstract shortened by UMI.) / IL-27, a novel member of the IL-12 family that is produced early by antigen-presenting cells (APCs), can promote T cell proliferation as well as the production of interferon-gamma by naive T lymphocytes. Recent studies have found that elevated expression of IL-27 has been detected in the synovial membranes and fluid of RA. Herein we investigated the in vitro effects of IL-27, alone or in combination with inflammatory cytokine TNF-alpha or IL-Ibeta on the pro-inflammatory activation of human primary FLS isolated from RA patients and normal control subjects, and the underlying intracellular signaling molecules were also studied. We found that the plasma concentration of IL-27 in RA patients (n=112) was significantly higher than that in control subjects (n=46). Both normal and RA-FLS constitutively express functional IL-27 receptor heterodimer, gp130 and WSX-1, with more potent IL-27-mediated activation of signal transducers and activators of transcription (STAT)1 in RA-FLS. IL-27 was found to induce significantly higher cell surface expression of intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 and release of inflammatory cytokine IL-6, chemokine CCL2, CXCL9, CXCL10 and matrix metalloproteinase (MMP)-1 of RA-FLS than that of normal FLS (all p &lt; 0.05). The above findings therefore provide a new insight into the IL-27-activated immunopathological mechanisms mediated by distinct intracellular signal transductions in joint inflammation of RA and may have important therapeutic implications. / In the present study, we have investigated the mechanisms of the activation of human fibroblast-like synoviocytes (FLS) induced by various stimuli including interleukin (IL)-27, tumor necrosis factor (TNF)-alpha and IL-beta. The activation of human FLS was studied in terms of the release of cytokines and chemokines and the expression of adhesion molecules. / We investigated the in vitro effects of uric acid crystals, alone or in combination with inflammatory cytokine TNF-alpha or IL-beta on the pro-inflammatory activation of human FLS from RA patients and normal control subjects, and the underlying intracellular signaling molecules were also determined. In the present study, uric acid crystals were found to result in a significant increase of inflammatory cytokine IL-6, chemokine CXCL8 and MMP-1 from both normal and RA-FLS (all p &lt; 0.05). Moreover, additive or synergistic effect was observed in the combined treatment of uric acid crystals and TNF-alpha or IL-1beta on the release of IL-6, CXCL8 and MMP-1 from both normal and RA-FLS. Further investigations showed that the release of inflammatory cytokine, chemokine and matrix metalloproteinase stimulated by uric acid crystals was differentially regulated by intracellular activation of extracellular signal-regulated kinase (ERK) and JNK pathways. Our results therefore provide a new insight into the endogenous danger signal uric acid crystals-activated immunopathological mechanisms mediated by distinct intracellular signal transductions in joint inflammation, and also provide biochemical basis for the development of new modality for inflammatory rheumatic diseases. / Chen, Dapeng. / Adviser: Wong Chun Kwok. / Source: Dissertation Abstracts International, Volume: 73-04, Section: B, page: . / Thesis (Ph.D.)--Chinese University of Hong Kong, 2011. / Includes bibliographical references (leaves 203-240). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [201-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.

Recomendações para rastreamento de Tuberculoses Latente (TBL) em pacientes que receberão tratamento com antagonistas do TNF-alfa (anti- TNF) permanecem controversas para regiões endêmicas Objetivo: Esse estudo buscou demonstrar a eficácia em longo prazo do rastreamento e tratamento da TBL em pacientes portadores de Artrite Reumatoide (AR) recebendo anti-TNF. Métodos: 202 pacientes com AR, antes do início do anti-TNF, foram rastreados para TBL por meio do teste tuberculínico (TT), Radiografia de tórax (RX) e história de prévia de exposição à tuberculose (EXP). Todos os pacientes foram seguidos com intervalos de um a três meses. Resultados: 85 pacientes (42%) foram tratados com um único agente anti-TNF e 117 pacientes (58%) mudaram de anti-TNF uma ou duas vezes. O rastreamento para TBL foi positivo em 66 pacientes, 44 apresentaram TT positivo, 23 apresentavam história de exposição (EXP), e 14, alterações radiográficas (RX). EXP isoladamente foi responsável por 14 diagnósticos em pacientes TT negativos. Pacientes portadores de TBL receberam tratamento com Isoniazida (300 mg/dia por seis meses) e nenhum deles desenvolveu TB. Durante os seguimentos, o TT foi repetido em 51 pacientes. A conversão foi observada em cinco: três foram diagnosticados com TBL e dois com TB ativa (14 e 36 meses após receber terapia anti-TNF), sugerindo nova exposição a TB. Conclusão: O rastreamento e tratamento da TBL antes do início da terapia com anti-TNF é efetiva em regiões endêmicas, e reforça a relevância da história de contato com TB para o diagnóstico da TBL em pacientes com AR / Recommendations for screening of latent tuberculosis infection (LTBI) in patients eligible for anti-TNF agents remain unclear in endemic regions. Objective: This study aimed to evaluate the long-term efficacy of LTBI screening/treatment in patients with rheumatoid arthritis (RA) receiving TNF blockers. Design: 202 RA patients were screened for LTBI prior to receiving anti-TNF treatment, by means of tuberculin skin test (TST), chest radiography (X-Ray), and history of tuberculosis exposure (EXP). All subjects were regularly followed at 1- to 3-month intervals. Results: Eighty-five patients (42%) were treated with a single anti-TNF agent, and 117 patients (58%) switched anti-TNF agents once or twice. LTBI screening was positive in 66 patients, 44 presented positive TST, 23 had a history of EXP, and 14, abnormal X-Ray. Exposure alone accounted for LTBI diagnosis in 14 patients with negative TSTs. LTBI patients were treated with Isoniazid (300 mg/day during six months) and none developed TB. During follow up, TST was repeated in 51 patients. Conversion was observed in five: three were diagnosed with LTBI and two with active TB (14 and 36 months after receiving anti-TNF therapy, suggesting new TB exposure). Conclusion: LTBI screening and treatment prior to anti-TNF treatment is effective in endemic areas and reinforces the relevance of contact history for diagnosing LTBI in RA patients

Introdução: A vacinação contra a influenza pandêmica A/H1N1 resultou em soroproteção em mais de 85% dos indivíduos saudáveis. Entretanto, dados em pacientes com artrite reumatoide (AR) são escassos. Objetivos: O objetivo deste estudo é avaliar a imunogenicidade e a segurança em curto prazo da vacina contra influenza pandêmica A/H1N1 em pacientes com AR e a influência da atividade da doença e da medicação nesta resposta. Métodos: Trezentos e quarenta pacientes adultos com AR em seguimento e tratamento regular e 234 controles saudáveis foram examinados antes e 21 dias após receber uma dose da vacina sem adjuvante contra influenza A/California/7/2009. A atividade da doença (DAS28), o tratamento em uso e os títulos de anticorpos também foram avaliados. As taxas de soroproteção (títulos de anticorpos >= 1:40) e soroconversão (percentagem de pacientes com aumento de título de anticorpos maior ou igual a 4, se o título pré- vacinal fosse maior ou igual a 1:10; ou título pós-vacinal de pelo menos 1:40, se o título pré-vacinal era menor que 1:10), as médias geométricas dos títulos (MGT) e o fator de incremento das médias geométricas (FI-MGT) foram calculados. Os eventos adversos foram também registrados. Resultados: Os pacientes com AR e os controles tinham taxas pré-vacinais de soroproteção (10,8% vs. 11,5%) e MGT (8,0 vs. 9,3) comparáveis (p>0,05). Após a vacinação, foi observada redução significativa na resposta dos pacientes com AR versus controles (p<0,001) em todos os desfechos sorológicos: taxas de soroproteção (60,0 vs. 82,9%) e soroconversão (53,2% vs. 76,9%), MGT (57,5 vs. 122,9) e FI-MGT (7,2 vs. 13,2). A atividade de doença não prejudicou a soroproteção ou a soroconversão e se manteve estável em 97,4% dos pacientes. O metotrexato e o abatacepte foram associados à redução da resposta vacinal. A vacinação foi bem tolerada, com poucos efeitos adversos. Conclusão: Os dados confirmaram tanto a segurança em curto prazo como, diferente da maioria dos trabalhos com influenza sazonal, a redução da soroproteção em pacientes com AR, não relacionada à atividade de doença e à maioria das medicações em uso (com exceção do metotrexato e do abatacepte). A extrapolação da resposta imunológica de uma vacina para outra pode não ser possível e estratégias específicas de imunização (possivelmente em duas doses) podem ser necessárias / Background: Pandemic influenza A/H1N1 vaccination yielded seroprotection in more than 85% of healthy individuals. However, similar data are scarce in rheumatoid arthritis (RA) patients. Objectives: The objective of this study is to evaluate the immunogenicity and the short-term safety of anti- pandemic influenza A/H1N1 vaccine in RA patients, and the influence of disease activity and medication to the response. Methods: Three hundred and forty adult RA patients in regular follow-up and treatment, and 234 healthy controls were assessed before and 21 days after adjuvant-free influenza A/California/7/2009 vaccine. Disease activity (DAS28), current treatment and anti-pandemic influenza A/H1N1 antibody titres were also evaluated. Seroprotection (antibody titre >=1:40) and seroconversion (the percentage of patients with a fourfold or greater increase in antibody titre, if prevaccination titre was 1:10 or greater, or a postvaccination titre of 1:40 or greater, if prevaccination titre was less than 1:10) rates, geometric mean titres (GMT) and factor increase in geometric mean titre (FI-GMT) were calculated and adverse events registered. Results: RA patients and controls showed similar (p>0.05) prevaccination seroprotection (10.8% vs. 11.5%) and GMT (8.0 vs. 9.3). After vaccination a significant reduction (p<0.001) was observed in all endpoints in RA patients versus controls: seroprotection (60.0 vs. 82.9%; p<0.0001) and seroconversion (53.2% vs. 76.9%) rates, GMT (57.5 vs. 122.9) and FI-GMT (7.2 vs. 13.2). Disease activity did not preclude seroprotection or seroconversion and remained unchanged in 97.4% of patients. Methotrexate and abatacept were associated with reduced responses. Vaccination was well tolerated with minimal adverse events. Conclusions: The data confirmed both short-term anti-pandemic A/H1N1 vaccine safety and, different from most studies with seasonal influenza, reduced seroprotection in RA patients, unrelated to disease activity and to most medications (except methotrexate and abatacept). Extrapolation of xii immune responses from one vaccine to another may therefore not be possible and specific immunization strategies (possibly booster) may be needed

Background: Rheumatoid arthritis (RA) is characterised by excessive production of tumour necrosis factor alpha (TNFα). This leads to rheumatoid cachexia, a condition characterised by increased resting energy expenditure (REE) and loss of fat-free mass (FFM) leading to functional disability, decreased strength and balance. The aims of this research work was to: a) to develop a new REE equation in order to continuously monitor abnormal changes in REE in the RA population, b) to investigate if smoking further enhances hypermetabolism and c) to examine if the new anti-TNFα medication reverses this metabolic abnormality. Methods: 68 patients with RA were assessed for demographic and anthropometrical characteristics, REE (indirect calorimetry), body composition (bioelectrical impedance), and disease activity [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), disease activity score 28 (DAS28) and health assessment questionnaire (HAQ)]. 20 of the total 68 patients, about to start anti-TNFα therapy, underwent the exact same aforementioned procedures but on three separate occasions (Baseline: two weeks prior to anti-TNFα treatment, Time-1 and Time-2: two weeks and three months, respectively, after the drug had been introduced. Results: Study 1: Based on FFM and CRP, a new equation was developed which had a prediction power of R2=0.76. The new equation revealed an almost identical mean with measured REE (1645.2±315.2 and 1645.5±363.1 kcal/day, p>0.05), and a correlation coefficient of r=0.87 (p=0.001). Study 2: Smokers with RA demonstrated significantly higher REE (1513.9±263.3 vs. 1718.1±209.2 kcal/day; p=0.000) and worse HAQ (1.0±0.8 vs. 1.7±0.8; p=0.01) compared to age and FFM matched RA non-smokers. The REE difference was significantly predicted by the interaction smoking/gender (p=0.04). Study 3: Significant increases were observed in REE (p=0.002), physical activity (p=0.001) and protein intake (p=0.001) between the three times of assessment. Moreover, disease activity significantly reduced [ESR (p=0.002), DAS28 (p=0.000), HAQ (p=0.000) and TNFα (p=0.024)] while FFM and total body fat did not change (both at p>0.05). Physical activity and protein intake were found to be significant within-subject factors for the observed REE elevation after 12-weeks on anti-TNFα treatment (p=0.001 and p=0.024, respectively). Conclusions: Findings from the first study revealed that the newly developed REE equation provides an accurate prediction of REE in RA patients. Moreover, the results from the second study showed that cigarette smoking further increases REE in patients with RA and has a negative impact on patients’ self-reported functional status. Finally, our data from the third study suggest that REE remains elevated not because of the maintenance of the RA-related hypermetabolism but due to the concomitant significant increases in physical activity and protein intake.

Diss. (sammanfattning) Stockholm : Karol inst., 2003. / Härtill 6 uppsatser. ISBN tilldelat efter tryckningen.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2007. / Härtill 4 uppsatser.

A artrite reumatóide é uma doença inflamatória crônica associada a alta morbidade, perda da produtividade e redução da expectativa de vida. Os pacientes requerem uma atendimento multidisciplinar para o controle da doença, reduzindo a inflamação e prevenindo a atrofia e deformação articulares. A estimulação elétrica nervosa transcutânea (TENS) tem se demonstrado no controle da dor articular, mas ainda há controvérsias sobre sua eficácia na reabilitação funcional da mão nesses pacientes. Este é um estudo cego, placebo-controlado, cruzado para comparar parâmetros funcionas da mobilidade da mão em pacientes com artrite reumatóide antes, durante e ao final de um período de 12 semanas de aplicação de TENS-burst em pontos sensitivos do membro superior. Na aplicação terapêutica utilizou-se intensidade de corrente de 10mA para estimulação das articulações metacarpofalangeanas e 20mA para os pontos sensorias do braço. Após uma pausa de um mês no tratamento, os pacientes que inicialmente receberam a estimulação terapêutica passaram a receber a estimulação placebo e vice-versa. Os resultados mostraram que a eletroestimulação terapêutica produziu mudanças positivas graduais e lineares na reabilitação funcional da mão analisado-se parâmetros de força e precisão de preensão das mãos, levando os pacientes à uma independência na execução de atividade de vida diária. O tratamento placebo mostrou-se ineficiente para a recuperação dos parâmetros avaliados. As habilidades conquistadas pelos pacientes que receberam inicialmente a eletroestimulação terapêutica foram perdidas durante o período de repouso, sugerindo que a manutenção da função da mão depende da continuidade do tratamento ao longo do tempo / Rheumatoid arthritis is a chronic inflammatory disease associated with high morbidity, loss of productivity and reduced life expectancy. Patients require multidisciplinary treatment to control the disease by reducing inflammation and preventing atrophy and joint deformation. Transcutaneous electrical nerve stimulation (TENS-burst) has been shown to control joint pain, but there is still controversy about its efficacy in functional hand rehabilitation in these patients. This is a blind, placebo-controlled, crossover study to compare the functional parameters of the mobility of the hand in rheumatoid arthritis patients before, during and after a period of 12 weeks of application of TENS- burst in the sensory points of the arm and metacarpophalangeal joints . In therapeutic application we used a current of 10mA for stimulation of joints and 20mA for the sensory points of the arm. After a month-long pause in treatment, patients who initially received therapy stimulation began receiving the placebo stimulation and vice versa. The results showed that therapeutic electrical stimulation produced gradual and linear positive changes in functional rehabilitation of the hand, accessed by analysis of strength and accuracy parameters of prehension, leading patients to independence in performing their daily living activities. The placebo treatment was inefficient for the recovery of the parameters evaluated. Skills achieved by patients who initially received therapeutic TENS-burst were lost during the rest (washing out) period, suggesting that the maintenance of hand function in rheumatoid artherits patients depends on the continuity of TENS-burst treatment